Lorsilan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorsilan

Property Description
Active ingredient Lorazepam
Form Tablet, oral solution, injectable solution
Pharmacological class Benzodiazepine / Central Nervous System (CNS) depressant
General purpose Anxiolysis (calming) and sedation
Origin Synthetic compound

Lorsilan is a trade name for a pharmaceutical product whose single active ingredient is Lorazepam, a synthetically derived chemical compound classified as a powerful CNS depressant. The active substance, Lorazepam, belongs to the Benzodiazepine family, a defined pharmacological class used for modulating neural activity. This medication is available solely by prescription and is clinically recognized for its short to intermediate duration of action compared to older agents in its class.

Classification, Composition, and General Purpose

Lorsilan is defined by its active component, Lorazepam, and is categorized as a single-ingredient product of synthetic origin. As a member of the Benzodiazepine class, it is grouped with agents that function as anxiolytics and anticonvulsants. The primary general purpose of the medication is to provide rapid relief from excessive tension by inducing anxiolysis (anxiety relief) and sedation (calmness). As a potent Benzodiazepine, Lorazepam is utilized for its effects on the CNS to help stabilize and calm overactive nerve signals in the brain.

Lorazepam is clinically recognized for its efficacy in managing acute seizure disorders. This recognition supports the understanding that this medication has a vital, generalized role in controlling episodes of intense nervous excitement and stabilizing neural activity.

Available Forms

The active ingredient is formulated into several high-level pharmaceutical preparations to suit various administration needs. These forms include the standard tablet for oral ingestion, a liquid oral solution or concentrate, and a sterile injectable solution. This form flexibility—specifically the availability of a rapidly acting parenteral form—is a key differentiating feature, ensuring the compound can be delivered effectively whether a patient requires continuous relief or prompt systemic access.

Regulatory References

  1. WHO Essential Medicines List for Lorazepam
  2. Lorazepam on WHO EML

What side effects are possible with Lorsilan?

Possible side effects and safety information

The safety profile for Lorsilan (Lorazepam) is officially documented by regulatory authorities and focuses primarily on effects related to Central Nervous System (CNS) depression and the potential for dependence.


Common and Expected Adverse Reactions

Adverse reactions classified as Common in regulatory documentation generally include those directly related to the medicine's depressant activity. These frequently reported effects include sedation, dizziness, weakness, and unsteadiness (ataxia). Less frequent, or uncommon, effects may include confusion, sleep disturbance, and changes in emotions.


Serious Adverse Reactions and Safety Constraints

The labeling details several serious adverse reactions, including the significant risk of respiratory depression, which can be life-threatening, particularly with the concomitant use of opioids or other CNS depressants. The medicine carries an explicit risk of developing physical and psychological dependence, and severe withdrawal symptoms (including seizures) can occur upon abrupt cessation, even after short-term therapeutic use. Paradoxical reactions, such as increased agitation or aggression, are also documented.


Population and Duration-Related Safety Notes

The risk of dependence is officially stated to increase with higher doses and longer durations of use. Safety information includes specific constraints for vulnerable groups: older adults are noted as being more susceptible to sedative effects, which increases the risk of falls and fractures. Use is often noted as contraindicated in patients with severe hepatic insufficiency due to the risk of worsening liver-related conditions.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Lorazepam (Lorsilan) is formally documented in regulatory labeling as manifesting primarily through a spectrum of Central Nervous System (CNS) depression. Recognized presentations range from drowsiness, excessive sleepiness, and motor impairment such as ataxia (loss of co-ordination) and hypotonia, progressing to a state of confusion and ultimately loss of consciousness or coma. Accompanying physiological signs may include hypotension (low blood pressure).

Regulators state that overdose carries the significant risk of life-threatening outcomes, including fatal respiratory depression and death. This risk is explicitly noted as being substantially increased by the concurrent use of Lorazepam with other CNS depressants, particularly opioids.

Immediate medical attention is required for any symptom cluster involving profound sedation, respiratory difficulty (hypoventilation or apnea), or a major change in consciousness, as defined in official prescribing information.

Management measures described in regulatory documents emphasize symptomatic and supportive treatment, including the essential maintenance of a patent airway and monitoring of vital signs. The benzodiazepine antagonist Flumazenil may be utilized for reversal, but its use is subject to specific warnings regarding the potential to precipitate seizures or acute withdrawal in chronic users. Furthermore, regulatory labels indicate that elderly or debilitated patients are more susceptible to the severe sedative effects of an overdose.

Therapeutic Uses of Lorsilan

What Lorsilan Treats: Main Uses and Benefits

Relief for Acute and Chronic Anxiety Symptoms

Lorsilan is commonly used to help with the management of anxiety disorders and the short-term relief of pronounced symptoms related to excessive tension and worry. This domain addresses symptom clusters that create noticeable physiological strain and interfere with functional stability. The medication is generally used to relieve anxiety and may assist in addressing insomnia.

The medication may be applied in addressing conditions such as anxiety disorders, anxiety-driven insomnia, acute episodes of agitation, and convulsive status epilepticus (seizures).

Management of Acute Symptom Crises

The medication is commonly used in situations involving acute symptomatic episodes of neurological or behavioral overactivity, including the management of convulsive status epilepticus (continuous seizures). It may also be applied in addressing agitation and the symptoms, such as tremors, associated with acute alcohol withdrawal syndrome. This use assists with symptom stabilization, which is relevant in clinical settings requiring temporary support for episodes of heightened discomfort.

“This medication is commonly applied across domains where additional symptomatic support is needed, particularly when patients experience heightened discomfort or tension.”

Supportive Relief and Procedural Assistance

Lorsilan is relevant in contexts involving heightened systemic burden where supportive calming is appropriate. This includes providing assistance for sleep difficulty when it stems directly from underlying worry, and is commonly used as a premedication before medical or dental procedures where symptomatic support is needed. This supportive application contributes to easing the overall symptom load during difficult episodes and helps support general well-being during symptomatic phases.


Quick Fact: Support for Symptoms of Increased Neurological Activity Lorsilan is considered relevant for easing symptoms of increased neurological or muscular activity, such as uncontrolled seizing and acute tremors.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Lorsilan?

Lorsilan eligibility is defined by absolute prohibitions and specific restrictions based on a patient's pre-existing health status, as documented by regulatory bodies.

Populations for whom use is contraindicated include those with known hypersensitivity to lorazepam or any benzodiazepine, as well as patients diagnosed with acute narrow-angle glaucoma, myasthenia gravis, and severe hepatic insufficiency or encephalopathy.

For age-related eligibility, use is established for adults. Older adults (geriatric) are eligible but must receive a mandatory reduced initial dose due to increased sensitivity. Use is not recommended for the general treatment of anxiety in children under 12 years of age, though it may be used for specific acute conditions.

Use is generally avoided or not recommended during pregnancy, particularly the first and last trimesters, and in mothers who are breastfeeding.

Conditional eligibility applies to patients with compromised respiratory function (e.g., sleep apnea) or impaired renal function, all of whom require caution. The drug is also not recommended for patients with a primary depressive disorder or psychosis. These restrictions collectively define the scope of the eligible patient population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Lorsilan (Lorazepam) identifies two primary categories of clinically significant interactions: those involving pharmacodynamic additive effects and those involving pharmacokinetic modification of the drug's clearance.

Pharmacodynamic Reinforcement

Co-administration with other Central Nervous System (CNS) depressants, including opioids, barbiturates, and some antipsychotics or sedative antihistamines, significantly increases the risk of profound sedation and respiratory depression. The combination with opioids is restricted in labeling due to the life-threatening risks associated with additive CNS effects. Additionally, concurrent use of Alcohol (Ethanol) is documented to reinforce these depressant effects. A specific interaction with Clozapine may lead to marked sedation, delirium, and respiratory arrest, as noted in official prescribing information.


Pharmacokinetic and Exposure Modification

Lorsilan is primarily cleared through a metabolic process called glucuronidation. Certain medicines, specifically Valproate (Valproic Acid) and Probenecid, are documented inhibitors of this process. Co-administration with either of these substances results in reduced clearance and an increase in the plasma concentration of Lorsilan. Regulatory documents mandate that the Lorsilan dosage must be reduced by approximately 50% when either Valproate or Probenecid is taken concurrently to prevent excessive exposure.


Population and Condition Cautions

The regulatory profile notes that elderly and debilitated patients may be more susceptible to the additive sedative effects of Lorsilan and other CNS depressants. Furthermore, use is contraindicated in patients with conditions such as Acute Narrow-Angle Glaucoma.

Mechanism of Action

How Lorsilan Works

Lorsilan functions as an inhibitor of the intracellular enzyme XYZ Kinase. This enzyme is critically involved in the signaling cascade responsible for osteoclast activation, differentiation, and survival.

The binding of Lorsilan to the active site of XYZ Kinase limits its enzymatic phosphorylation activity, thereby disrupting the downstream molecular signaling within the cell. This interruption reduces the signals that promote excessive osteoclast formation and function. The resulting cellular modulation includes a decrease in the production and secretion of pro-inflammatory cytokines that contribute to osteoclast support.

The system-level physiological consequence of this targeted inhibition is the modulation of the balance between osteoblast (bone formation) and osteoclast (bone resorption) activity in the skeletal microenvironment. The reduced osteoclast activity leads to decreased overall bone resorption.

Dosage and Administration Information

Administration Routes and Dosing

Lorsilan (Lorazepam) is administered via Oral (tablet or concentrate) for routine use, or via Intravenous (IV) or Intramuscular (IM) injection for acute needs, such as in convulsive status epilepticus. All administration procedures and doses must strictly follow established clinical practice.

Administration Detail Clinical Parameters
Standard Oral Dosing For anxiety, the initial daily dose is typically 2 to 3 mg in divided doses, with a maximum of 10 mg/day, though a maximum of 4 mg/day is frequently utilized for short-term use. Insomnia doses are 2 to 4 mg taken once daily at bedtime.
Acute IV Dosing The standard initial dose for status epilepticus is 4 mg administered via slow IV injection, which may be repeated once after a 10 to 15-minute observation period, up to a maximum total of 8 mg.
Dosing for Older Adults The initial dose for older or debilitated patients should be reduced to approximately 1 to 2 mg per day in divided doses, with the initial total daily dose not exceeding 2 mg.
Special Preparation The injectable solution must be diluted 1:1 with a compatible diluent (e.g., Normal Saline) immediately prior to IV use. The IV injection rate should generally not exceed 2 mg/minute.
Duration of Use Treatment is intended for short periods only, typically 2 to 4 weeks. Continuous long-term use is not systematically assessed or generally recommended.

Oral administration may be taken with or without food. When a dose is missed, it is advised not to take a double dose to catch up.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lorsilan

Evidence for Use in Acute Seizure Management

Research exploring the use of Lorazepam in acute seizure management, specifically for convulsive status epilepticus, has largely relied on Randomized, Controlled Trials (RCTs) and comprehensive analyses of these studies. This evidence base was studied for the primary research question of whether Lorazepam was associated with a time to seizure cessation, a specific outcome measured in the studies. The research examined groups of patients, including both adults and children, who presented in emergency situations. Studies reported observations related to the measured time to control of seizure activity during an acute episode. These trials often compared Lorazepam with other existing medications used to manage the same condition, helping contextualize the data within current treatment protocols.

Evidence for Short-Term Anxiety and Agitation

Lorazepam was studied for its application in conditions associated with acute or disruptive episodes, such as anxiety disorders and pronounced states of excessive tension or agitation. The majority of research consists of short-term, placebo-controlled and active-controlled RCTs that typically observed patients for intervals up to four weeks. Studies describe observed patterns related to the measured change in symptom severity during short-term trials on scales that monitor patient-reported outcomes describing perceived discomfort. It is important to understand that the research base is built upon evidence structured around short-term use only. Consequently, long-term effects are not fully established, and follow-up durations were limited in the pivotal controlled trials.

What is Still Uncertain About Lorsilan

Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. The primary uncertainty surrounds the long-term effects and functional outcomes beyond the initial, short treatment periods for which the medication is generally studied. The evidence quality varies across studies, particularly in less acute scenarios like procedural premedication, where findings were mixed regarding patient recovery. There are also notable gaps, as data for certain groups remain insufficient, particularly concerning the use of the drug in certain comorbid conditions or for extended periods.

Key Studies & References

  1. Lorazepam premedication: lack of recall and relief of anxiety (RCT)
  2. Lorazepam - StatPearls - NCBI Bookshelf (Review of Indications and Uses)
  3. Alcohol Use: Treatment for alcohol withdrawal - CAMH (Clinical Guideline)
  4. Lorazepam - Electronic Essential Medicines List (eEML) - WHO

Frequently Asked Questions (FAQ)

Common questions about Lorsilan (FAQ)


Q: What conditions is Lorsilan officially approved to treat?

According to official prescribing information, Lorsilan is approved to treat anxiety disorders and the short-term symptoms of anxiety, including insomnia linked to stress. The medication is also indicated for use as a pre-operative sedative before medical procedures.


Q: How is Lorsilan typically used in a hospital setting?

In hospital settings, Lorsilan is often administered by injection for the acute management of conditions such as convulsive status epilepticus (a type of seizure). Official product information notes it is also used before surgeries as a premedication to provide sedation and relieve anxiety.


Q: Is Lorsilan used for generalized anxiety or specifically for panic attacks?

Lorsilan is indicated for the general management of anxiety disorders and associated anxiety symptoms. As a fast-acting agent, it is often utilized to address acute, intense anxiety symptoms, which can include those associated with a panic episode.


Q: Can Lorsilan be used as a pre-medication before medical procedures?

Yes, regulatory documents state that Lorsilan is officially indicated for pre-operative use. Its purpose is to induce sedation, provide anxiety relief, and produce anterograde amnesia—meaning it reduces recall of events during the procedure.


Q: How quickly does the effect of a standard Lorsilan tablet begin to be noticed?

Official information indicates that the standard oral tablet is rapidly absorbed by the body. While peak concentrations are typically reached around two hours after administration, the onset of effects may begin before that peak.


Q: Do the sublingual and oral forms of Lorsilan have different onset times?

Yes, the time it takes for the drug to reach its peak level in the blood differs depending on the form. Regulatory data indicates that sublingual administration (under the tongue) generally achieves peak levels faster than the standard oral tablet.


Q: What factors in the body affect how long Lorsilan's effects last?

The body eliminates Lorsilan through a metabolic process in the liver called glucuronidation. Official data reports the time it takes for half the drug to be eliminated from the bloodstream, known as the half-life, is typically between 12 and 15 hours. Official prescribing information notes that clearance may be slower in individuals with impaired liver function.


Q: Does the maximum effect of Lorsilan occur immediately after the onset of action?

No, the maximum effect of Lorsilan does not usually occur immediately after the onset of action. The strongest effects are typically reached near the peak concentration in the bloodstream, which is often about two hours after swallowing the standard tablet.


Q: Does Lorsilan affect long-term or short-term memory?

Official prescribing information lists memory impairment as a possible adverse reaction. This can include anterograde amnesia, where a person may experience difficulty forming new memories after taking the medication.


Q: What types of vision changes have been associated with Lorsilan use?

Official documentation indicates that changes to vision are a possible adverse reaction. The most commonly described specific effect is blurred vision.


Q: Is it possible to experience a 'hangover' feeling the morning after taking Lorsilan for sleep?

Yes, it is possible to experience lingering effects. Common side effects like sedation, drowsiness, and dizziness can persist into the following day. Official labeling indicates these effects are more frequently reported with higher doses or in older adults.


Q: What measures are described for managing common side effects like dry mouth from Lorsilan?

Dry mouth is a documented side effect of Lorsilan. Patient information resources describe common coping strategies such as drinking frequent sips of water, chewing sugar-free gum, or using sugar-free pastilles to help manage the symptom.


Q: Do the side effects of Lorsilan generally improve over the first few weeks of use?

Studies and official information indicate that common side effects, such as initial drowsiness and dizziness, are commonly reported to improve. These effects often lessen over the first week or two as the body adjusts to the medication.


Q: What is meant by the term 'physical dependence' in relation to Lorsilan?

Physical dependence is a documented risk and refers to the body's physiological adaptation to the continuous presence of the drug. Regulatory warnings indicate that abrupt cessation in physically dependent individuals can lead to severe withdrawal reactions.


Q: How does the body develop tolerance to the effects of Lorsilan?

Tolerance is a chemical process where the medication's effectiveness decreases over time with regular use. Regulatory-derived resources explain that this occurs as the brain chemically adapts to the drug, often by altering its GABA receptors.


Q: Is rebound anxiety an expected effect when Lorsilan is stopped?

Yes, the official labeling warns that discontinuation of Lorsilan can cause rebound phenomena. This is a form of withdrawal where the original symptoms, such as anxiety and insomnia, may return, potentially more intensely than before treatment.


Q: How do regulatory bodies define the risk of addiction for Lorsilan?

The official regulatory label explicitly carries a warning regarding the risks of abuse, misuse, and addiction. Addiction is generally defined in this context as the compulsive seeking and use of the drug, despite the resulting negative consequences and harm.


Q: What is the general recommended approach for gradually stopping Lorsilan?

Official regulatory documents contain warnings against suddenly stopping Lorsilan. Instead, a gradual reduction in dosage, known as a taper, is required to minimize the risk of acute withdrawal reactions.


Q: Does taking Lorsilan 'as needed' versus daily change the risk of dependence?

The official risk profile states that the likelihood of physical dependence increases with a longer duration of use and higher daily doses. Therefore, the medication should be limited to the lowest effective dose for the shortest necessary period.


Q: What is the difference between physical dependence and addiction for this type of medication?

Official warnings distinguish between the two terms. Physical dependence is the body’s simple physiological adaptation to the drug, while addiction is a behavioral pattern characterized by compulsive use, craving, and seeking the drug despite negative consequences.


Q: Do herbal supplements commonly interact with Lorsilan?

Yes, official patient guidance recommends caution when combining Lorsilan with certain herbal remedies or supplements. Specifically, herbs intended for anxiety or insomnia, like valerian or passionflower, have the potential to amplify the sedative effects of the medication.


Q: Does Lorsilan come in a long-acting (extended-release) formulation?

Yes, in addition to the standard tablet and solution, an extended-release (ER) capsule formulation of the active ingredient, lorazepam, is available by prescription.


Q: What happens to the effect if a sublingual Lorsilan tablet is accidentally swallowed?

If a sublingual tablet is accidentally swallowed instead of being dissolved under the tongue, the drug will be absorbed through the gastrointestinal tract instead of the mouth. This change in administration typically results in a slower onset of action and a later time to reach maximum effect.


Q: Are there official guidelines regarding driving a vehicle while taking Lorsilan?

Yes, regulatory guidelines contain explicit warnings against driving or operating hazardous machinery. This restriction is due to the potential for side effects such as dizziness, drowsiness, and unsteadiness, which can impair a person's ability to drive safely.

How should Lorsilan be stored and disposed of?

Storage Conditions

Lorsilan (lorazepam) tablets and oral concentrate must be stored at Controlled Room Temperature, specifically defined as 20 to 25 C (68 to 77 F). The medication must be kept in a tightly closed container. The injectable solution requires strict protection from light and must not be frozen. Due to the risk of accidental ingestion and misuse, all forms of Lorsilan must be stored in a safe place and kept out of the reach of children.

Disposal Instructions

Lorazepam is a controlled substance, and regulatory guidance recommends disposal through an official drug take-back program (e.g., mail-back envelopes or collection sites) for unused or expired product. If a take-back option is unavailable, the medication should be mixed with an unappealing substance, sealed in a container, and discarded in the household trash. Identifying information on the prescription label must be scratched out before container disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorsilan found in:

A-Z Index: